Related Experiment Videos
Case report : carbamazepine therapy in schizophrenia
1Associate Professor & Head, Department of Psychiatry Kasturba Medical College Hospital Manipal, Karnataka.
Indian Journal of Psychiatry
|October 4, 2011
Summary
Carbamazepine showed promise in treating schizophrenia. Seven of nine patients resistant to standard treatments experienced symptom improvement with this anticonvulsant medication.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a complex psychiatric disorder with limited treatment options for non-responsive cases.
- Conventional antipsychotic medications are not effective for all schizophrenia patients.
- Identifying novel therapeutic agents for treatment-resistant schizophrenia is crucial.
Purpose of the Study:
- To evaluate the efficacy of carbamazepine in patients with schizophrenia who are non-responsive to conventional treatments.
- To assess carbamazepine's potential as an adjunctive or standalone therapy for schizophrenia.
Main Methods:
- A cohort of 9 patients diagnosed with schizophrenia according to Spitzer's Research Diagnostic Criteria was selected.
- Patients were treated with carbamazepine, either as monotherapy or in combination with neuroleptic drugs.
- Treatment response was assessed based on clinical improvement.
Main Results:
- Out of 9 patients treated, 7 showed significant clinical improvement.
- Carbamazepine demonstrated a positive effect on schizophrenia symptoms in treatment-resistant individuals.
- The combination of carbamazepine with neuroleptics appeared effective in some cases.
Conclusions:
- Carbamazepine may be a viable therapeutic option for schizophrenia patients refractory to standard treatments.
- Further research is warranted to confirm these findings and elucidate the mechanisms of action.
- Carbamazepine offers a potential new avenue for managing difficult-to-treat schizophrenia.
Related Concept Videos
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...